Zynerba Pharmaceuticals (ZYNE) executive Rosenberger sold 4,289 shares for $4,718 at $1.10
Insider transactions reported
Brian Rosenberger (executive at Zynerba Pharmaceuticals Inc., ZYNE) reported that they sold 4,289 shares for $4,718 at $1.10, and received 14,800 shares between Jul 18, 2022 and Jul 19, 2022. After these transactions the filing shows 107,511 shares held directly.
- Reporting person
- Rosenberger Brian
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 18, 2022 | Grant or award (A) | Common Stock1 | +14,800 | - | - | 111,800 direct |
| Jul 19, 2022 | Open-market sale (S) | Common Stock2 | -4,289 | $1.10 | $4,718 | 107,511 direct |
Holdings before and after
- Common Stock: 97,000 to 107,511 direct
Footnotes from the filing
- 1. On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 14,800 performance-based restricted stock awards granted in a prior year.
- 2. This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Rosenberger report in this ZYNE Form 4?
Brian Rosenberger (executive at Zynerba Pharmaceuticals Inc., ZYNE) reported that they sold 4,289 shares for $4,718 at $1.10, and received 14,800 shares between Jul 18, 2022 and Jul 19, 2022. After these transactions the filing shows 107,511 shares held directly.
How many ZYNE shares does Rosenberger hold after this filing?
The filing shows 107,511 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this ZYNE insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for ZYNE
Earlier insider filings at ZYNE
- Jul 20, 2022SEC Form 4: Anido Armando was granted 43,164 shares and sold $13,089 worth of shares (11,899 units at $1.10), increasing direct ownership by 5% to 611,688 units (for withholding tax)
- Jul 20, 2022SEC Form 4: Fickenscher James E was granted 20,800 shares and sold $6,614 worth of shares (6,013 units at $1.10), increasing direct ownership by 9% to 172,505 units to cover taxes
- Jun 17, 2022SEC Form 4: Kisner Daniel L was granted 23,109 shares and sold $40 worth of shares (40 units at $1.01), increasing direct ownership by 461% to 28,069 units
- Jun 17, 2022SEC Form 4: Federici William J was granted 23,109 shares and sold $40 worth of shares (40 units at $1.01), increasing direct ownership by 461% to 28,069 units
- Jun 17, 2022SEC Form 4: Stephenson Pamela was granted 23,109 shares and sold $40 worth of shares (40 units at $1.01), increasing direct ownership by 461% to 28,069 units
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Follow ZYNE and get a push notification the moment its next story breaks.